Last updated: 26 June 2019 at 1:41am EST

Dr. Jonathan Pachter Ph.D. Net Worth




The estimated Net Worth of Jonathan Pachter is at least $187 Tisíc dollars as of 13 May 2014. Dr Pachter owns over 1,000 units of Verastem Inc stock worth over $187,474 and over the last 13 years he sold VSTM stock worth over $0.

Dr D VSTM stock SEC Form 4 insiders trading

Dr has made over 1 trades of the Verastem Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of VSTM stock worth $7,620 on 13 May 2014.

The largest trade he's ever made was buying 1,000 units of Verastem Inc stock on 13 May 2014 worth over $7,620. On average, Dr trades about 125 units every 0 days since 2012. As of 13 May 2014 he still owns at least 66,955 units of Verastem Inc stock.

You can see the complete history of Dr Pachter stock trades at the bottom of the page.





Dr. Jonathan Pachter Ph.D. biography

Dr. Jonathan Pachter Ph.D. is the Chief Scientific Officer at Verastem Inc.



How old is Dr D?

Dr D is 63, he's been the Chief Scientific Officer of Verastem Inc since . There are 3 older and 13 younger executives at Verastem Inc. The oldest executive at Verastem Inc is Timothy Barberich, 72, who is the Independent Director.

What's Dr D's mailing address?

Jonathan's mailing address filed with the SEC is C/O VERASTEM, INC., 215 FIRST STREET, SUITE 440, CAMBRIDGE, MA, 02142.

Insiders trading at Verastem Inc

Over the last 13 years, insiders at Verastem Inc have traded over $5,883,823 worth of Verastem Inc stock and bought 3,873,819 units worth $28,318,633 . The most active insiders traders include Capital Management, L.P.Ra ..., Christoph H Westphal a Ansbert Gadicke. On average, Verastem Inc executives and independent directors trade stock every 28 days with the average trade being worth of $112,479. The most recent stock trade was executed by Dan Paterson on 5 August 2024, trading 3,245 units of VSTM stock currently worth $7,009.



What does Verastem Inc do?

verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com



Complete history of Dr Pachter stock trades at Verastem Inc

Človek
Trans.
Transakcia
Celková cena
Jonathan Pachter
Viceprezident a Head of Research
Kúpa $7,620
13 May 2014


Verastem Inc executives and stock owners

Verastem Inc executives and other stock owners filed with the SEC include: